Company Continues to Expand Its Scientific Expertise with Noted Expert in Utilizing Ketamine for Treatment Resistant DepressionNeonMind Biosciences Inc. an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that it has appointed Dr. Gustavo Vazquez, MD, PhD, a Professor of Psychiatry at …
Company Continues to Expand Its Scientific Expertise with Noted Expert in Utilizing Ketamine for Treatment Resistant Depression
NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that it has appointed Dr. Gustavo Vazquez, MD, PhD, a Professor of Psychiatry at Queen’s University in Kingston, Ontario, and a noted expert in mood disorders and ketamine utilization, to its Specialty Clinics Advisory Board
In his role on NeonMind’s Specialty Clinics Advisory board, Dr. Vazquez will leverage his considerable expertise in organizing and managing ketamine clinics to support NeonMind as it develops its company-branded, specialty clinics network to increase patient access to evidence-backed effective treatments including ketamine.
Dr. Vazquez is a global expert in utilizing ketamine for the treatment of mood disorders. He started his career in 1996 in Argentina...
Read Full Story: https://investingnews.com/news/psychedelics-investing/neonmind-strengthens-its-specialty-clinics-advisory-board-with-appointment-of-mood-disorders-and-ketamine-expert-dr.gustavo-vazquez-md-phd/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.